A PHASE 1, OPEN-LABEL, RANDOMIZED, 4-PERIOD, 2-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF MARSTACIMAB (PF-06741086) PREFILLED SYRINGE DEVICE AND PREFILLED PEN DEVICE FOLLOWING SUBCUTANEOUS ADMINISTRATION IN HEALTHY ADULT MALE PARTICIPANTS
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Marstacimab (Primary)
- Indications Haemophilia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 27 Sep 2022 Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting.
- 07 Jul 2022 Status changed from completed to discontinued.
- 29 Nov 2021 Status changed from suspended to completed.